In the United States, Epitalon is not FDA-approved. An HHS policy document describes enforcement discretion if issued as written; as of October 28, the OIRA record did not show publication.
Do not treat the document as a current access route until its official publication and effective status are confirmed. A research-use-only vial, a combination vial, an oral or nasal Epitalon product, and an ordinary online purchase are outside this policy.
October 28, 2026
What does the HHS policy actually allow for Epitalon?
HHS’s peptide policy covers six named peptide bulk drug substances while the 503A bulks list is addressed through rulemaking: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. It is an enforcement-discretion policy, not an FDA approval and not a blanket permission to sell or use any peptide product.
If officially issued as written, the document would limit Epitalon acetate enforcement discretion to situations where all of these conditions are present:
- A valid patient-specific prescription.
- Compounding by a State-licensed pharmacy, Federal facility, or licensed physician within the policy’s scope.
- Epitalon in the exact identity specified by HHS, as a subcutaneous or intramuscular injectable product dispensed in intermittent courses.
- One active pharmaceutical ingredient only. A vial combining Epitalon with another peptide is outside the policy.
- Bulk ingredient from an FDA-registered original manufacturer that complies with CGMP requirements, with a valid certificate of analysis and the required manufacturer information.
- Reporting of compounded products, serious adverse events, and quality problems to FDA MedWatch and relevant states.
- The required label: “This is a compounded drug product. Not for resale.”
- No co-packaged delivery device other than an FDA 510(k)-cleared syringe.
The policy also requires compliance with other applicable requirements of the Federal Food, Drug, and Cosmetic Act. Section 503A ties patient-specific compounding to a valid prescription and licensed pharmacy or physician route.
What does “intermittent courses” mean?
The document limits its described Epitalon enforcement discretion to injectable products dispensed in intermittent courses; it does not define a dosing schedule.
This also means an Epitalon nasal spray is not within the policy’s route limit. The allowed routes are subcutaneous or intramuscular injection only, in intermittent courses.
Why did HHS include Epitalon?
HHS says Epitalon had been in FDA’s Category 2 from September 2023 until April 22, 2026. FDA’s Center for Drug Evaluation and Research recommended against listing it, while the Pharmacy Compounding Advisory Committee voted in favor of inclusion. That advisory vote did not itself change the 503A bulks list.
For Epitalon, HHS points to lot records from FDA-registered facilities that include endotoxin, microbial, and residual-solvent results, with another lot adding solubility and elemental-impurity results. HHS also cites documented historical use and limited controlled human exposure that reported no side effects, with documented regimens described as intermittent rather than continuous.
That is not the same as an approved-drug review. FDA’s bulk-substance risk page says compounded Epitalon may pose immunogenicity risks from aggregation and peptide-related impurities, and that FDA has not identified safety-related information for the proposed route sufficient to know whether it would cause harm in humans. Compounded drugs are not FDA-approved, so FDA does not review their safety, effectiveness, or quality before marketing.
What is outside the Epitalon policy?
| Product or route | Covered by this HHS policy? | Why it matters |
|---|---|---|
| Prescription Epitalon injection in intermittent courses | Only if the policy is officially issued as written and every listed condition is met. | The pharmacy, sourcing, formulation, reporting, and labeling conditions all still apply. |
| Research-use-only Epitalon vial | No | HHS says the policy is intended to discourage research-use-only peptides supplied by foreign manufacturers; it does not cover those sellers. |
| Epitalon combined with another peptide | No | The policy permits only one listed peptide API per product. |
| Oral or nasal Epitalon | No | Appendix B limits Epitalon to subcutaneous or intramuscular injectable dosage forms in intermittent courses. |
| GHK-Cu or another peptide not listed | No | Only the six Appendix A peptides are within this interim policy. |
The route limit is important if an offer uses phrases such as “legal peptide” or “research grade.” Those labels do not replace the prescription, pharmacy, sourcing, single-ingredient, and route requirements. Questions about supplements and prescription medicines can also help frame a conversation with a pharmacist.
Can you buy Epitalon online right now?
If officially issued as written, the document would not authorize a direct-to-consumer purchase without a patient-specific prescription and a qualifying compounder. If an online service is involved, ask which State-licensed 503A pharmacy will dispense the prescription product, whether the product is Epitalon acetate alone, and whether the route and intermittent-course limit match Appendix B.
You also have two straightforward alternatives: use an FDA-approved peptide drug when one fits the condition being addressed, or wait for the final rulemaking decision on Epitalon. HHS says it may revisit the interim policy if a safety signal or product-quality issue arises.
Has the policy become a final rule?
Not from the policy itself. The policy says it applies until each peptide is addressed in a final rule as included or not included on the 503A bulks list. OIRA completed review of HHS’s “Interim Access Policy for Compounding Using Certain Peptides” on October 27, 2026, with the conclusion “Consistent with Change.” A Federal Register publication on October 30 has been reported, but that date is not confirmed by the HHS document.
For context, FDA’s 503A guidance explains that its interim bulk-substance policy operates while the agency develops the applicable bulks list through rulemaking.
Before you pursue Epitalon
- Ask the prescriber whether the intended product is Epitalon acetate and whether it is being prescribed as an intermittent course.
- Ask the dispensing pharmacy to identify its State license and confirm it is filling a patient-specific prescription under the HHS policy.
- Confirm the product contains Epitalon as its single active pharmaceutical ingredient, rather than a multi-peptide blend.
- Ask the pharmacy how the required certificate of analysis, labeling, and adverse-event reporting conditions are handled.
- Do not use a research-use-only listing as a substitute for the prescription-compounding route.
The smallest useful next step is to bring the policy’s exact route and prescription conditions to your prescriber or licensed pharmacy before considering any product. If sleep is part of your wellness routine, keep caffeine and sleep timing separate from decisions about a compounded medication.
By MakeTimeForWellness.com Wellness Team